Kenvue Q3: Revenue Beats But Earnings Fall For Third Time
Kenvue beat Q3 revenue estimates at $3.89 billion, driven by Self Care growth of 5.9%, but adjusted EPS fell to $0.29, missing consensus by the widest quarterly margin this year. The third consecutive
Kenvue Q3 EPS Miss Deepens as Acquisition Nears
NEW YORK, October 30 —
Even as Kenvue Inc. (KVUE) posted top-line growth and CEO Kirk Perry declared margin expansion, adjusted EPS of $0.29 missed the $0.37 analyst consensus by the widest quarterly gap this year. With KVUE delisting as the Kimberly-Clark acquisition completes, this quarterly report is the last investors will receive, leaving the contradiction between top-line growth and shrinking earnings power permanently unanswered.
- Adjusted EPS $0.29 vs. $0.37 consensus: second consecutive miss, widest margin of 2026.
- Net sales $3.89B beat $3.86B estimate; 3.2% YoY growth; Self Care up 5.9% to $1.66B.
- EPS fell three straight quarters: $0.32 Q1, $0.31 Q2, $0.29 Q3 2026.
Self Care Carried the Quarter
Kenvue makes the products that fill the medicine cabinet and bathroom shelf: Tylenol for pain, Benadryl for allergies, Zyrtec for seasonal symptoms, Nicorette for smokers quitting, and Listerine for oral care, alongside skincare lines Neutrogena and Aveeno. Carved from Johnson & Johnson in 2022, the company operates across the US, Europe, Asia-Pacific, and Latin America. In Q3 2026, Self Care posted 5.9% revenue growth to $1.66 billion, with Nicorette and Pepcid cited as standouts, and Tylenol gaining share despite lower seasonal illness incidence. Total organic growth was 2.9%, a clean volume and price split. Top-line execution was not the problem.
Margin Expansion Needs Explaining
Perry's claim of margin expansion sits uneasily against the sequential earnings trajectory. Three consecutive beats before this year, including a 23.1% upside surprise in Q1 2026, gave way to Q2's small miss and now Q3's wide one. Kenvue carries $8.61 billion in total debt against $1.11 billion in cash, with trailing free cash flow of $1.9 billion. Kimberly-Clark closed a $4.9 billion notes offering to finance the acquisition. With no guidance issued per the Q3 8-K filing, the question of what is compressing earnings below the operating line goes unanswered.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| KVUE | $37.1B | 15.6x | +36.1% |
| KDP | $48.8B | 14.2x | +30.0% |
| AMCR | $21.9B | 11.0x | +19.3% |
| GEHC | $34.6B | 14.0x | +2.0% |
| HLN | $38.1B | 14.0x | -7.6% |
| TFC | $58.5B | 9.9x | +10.5% |
An Open Question Now Belongs to Kimberly-Clark
Kenvue shares trade at $19.27, below the $19.50 analyst consensus target, at a forward P/E of 15.5x on trailing revenue of $15.41 billion. Four senior executives received equity grants priced at $17.20 per share on October 2 per Form 4 filings, below the current price. With delisting set as the Kimberly-Clark acquisition closes, the Q3 2026 report is the last standalone disclosure investors will ever see. The unresolved tension between top-line growth and shrinking earnings power passes to Kimberly-Clark to explain. Investors modeling Kenvue's contribution to KMB can use the DCF calculator or run the free Kenvue Inc. deep-dive →.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Did Kenvue meet earnings expectations in Q3 2026?
Kenvue beat revenue estimates at $3.89 billion versus $3.86 billion consensus, with 3.2% year-over-year growth. However, adjusted EPS came in at $0.29, missing the $0.37 consensus target by the widest quarterly margin this year.
Why is Kenvue's EPS falling despite revenue growth?
Management cited margin expansion for Q3, yet adjusted EPS has declined three quarters in a row: $0.32 in Q1, $0.31 in Q2, and $0.29 in Q3 2026. The article notes that no guidance was issued, leaving the source of earnings compression below the operating line unexplained.
What drove Kenvue's revenue growth in Q3?
Self Care products, including Tylenol, Benadryl, Zyrtec, Nicorette, and Listerine, grew 5.9% to $1.66 billion. Nicorette and Pepcid were cited as standouts, while Tylenol gained market share despite lower seasonal illness incidence.
Is this the last Kenvue earnings report?
Yes. As the Kimberly-Clark acquisition nears completion and Kenvue prepares to delist, the Q3 2026 report will be the company's final standalone disclosure. The unresolved questions about what is compressing earnings now pass to Kimberly-Clark to explain.
What is Kenvue's debt and cash position?
Kenvue carries $8.61 billion in total debt against $1.11 billion in cash, with trailing free cash flow of $1.9 billion. Kimberly-Clark secured a $4.9 billion notes offering to help finance the acquisition.
Kenvue posted Q3 2026 revenue of $3.89 billion, beating estimates on a 3.2% year-over-year gain, but adjusted EPS of $0.29 fell well short of the $0.37 analyst consensus — the second consecutive quarterly earnings miss. The company declined to provide guidance, citing its pending Kimberly-Clark acquisition that is now completing and will delist KVUE shares.